Nordwand Advisors, LLC Passage Bio, Inc. Transaction History
Nordwand Advisors, LLC
- $374 Billion
- Q3 2024
A detailed history of Nordwand Advisors, LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Nordwand Advisors, LLC holds 2,500 shares of PASG stock, worth $1,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,500Holding current value
$1,550% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PASG
# of Institutions
45Shares Held
32.7MCall Options Held
8.3KPut Options Held
400-
Orbimed Advisors LLC San Diego, CA10.1MShares$6.28 Million0.19% of portfolio
-
Vestal Point Capital, LP New York, NY6.05MShares$3.75 Million0.36% of portfolio
-
Versant Venture Management, LLC San Francisco, CA4.03MShares$2.5 Million7.06% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.55 Million2.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$1.28 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $33.8M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...